Overview

Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients, and Safety in Combination With L-dopa

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
This study will evaluate the safety and efficacy of administration of AFQ056 in combination with L-dopa, in reducing the number of L-dopa related dyskinesias in Parkinson's disease patients.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Novartis
Treatments:
Levodopa
Criteria
Inclusion Criteria:

- Patients with Parkinson's Disease

- Patients with L-dopa induced dyskinesia for at least 3 months

- Patients with L-dopa treatment for at least 3 years, stable for 1 month minimum

Exclusion Criteria:

- History of severe allergy to food or drugs

- Very low or high body weight.

- Prior surgery for Parkinson's Disease

- Smokers

Other protocol-defined inclusion/exclusion criteria may apply